Stocks
Innoviva, Inc.INVA
NASDAQHealthcareBiotechnology$22.03+0.27%
Price as of · delayed, not real-time
Specializing in royalty management and asset monetization for respiratory therapies, this firm holds key financial interests in blockbuster drugs like GlaxoSmithKline's Trelegy and Anoro. Investors monitor its performance due to stable royalty streams from FDA-approved treatments in high-demand therapeutic areas.
Market Cap: $1.4B52W Range: $16.52 – $25.15
Congressional Interest in Innoviva, Inc. (INVA)
2 members of Congress have disclosed 3 trades in Innoviva, Inc. (INVA), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 2 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
3
Unique Politicians
2
Buys
1
Sells
2
Who in Congress Is Trading INVA?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-03-25 | George Whitesides | sell | $250K – $500K |
| 2025-03-24 | George Whitesides | sell | $50K – $100K |
| 2016-11-02 | JAMES B. RENACCI | buy | $1K – $15K |